share_log

Theriva Biologics | 10-Q: Q3 2024 Earnings Report

Theriva Biologics | 10-Q: Q3 2024 Earnings Report

Theriva Biologics | 10-Q：2024財年三季報
美股SEC公告 ·  2024/11/13 00:32

Moomoo AI 已提取核心訊息

Theriva Biologics reported Q3 2024 financial results and clinical progress. Revenue was not reported, while net loss widened to $7.7 million from $3.3 million year-over-year. R&D expenses decreased 32% to $2.7 million due to lower clinical trial costs for VCN-01 and SYN-020. The company recorded $2.8 million in impairment charges for in-process R&D and goodwill.Theriva achieved target enrollment of 92 patients in its Phase 2b VIRAGE trial of VCN-01 for pancreatic cancer. The FDA granted Rare Pediatric Disease Designation to VCN-01 for retinoblastoma treatment. A Phase 1 trial of VCN-01 in brain tumors began enrolling patients. The company's cash position of $16.4 million is expected to fund operations into Q3 2025.Management is exploring strategic options and additional financing to advance clinical programs, particularly later-stage trials of VCN-01. The company faces uncertainty in obtaining sufficient funding to execute its business plan long-term, with its auditors expressing substantial doubt about its ability to continue as a going concern without additional capital.
Theriva Biologics reported Q3 2024 financial results and clinical progress. Revenue was not reported, while net loss widened to $7.7 million from $3.3 million year-over-year. R&D expenses decreased 32% to $2.7 million due to lower clinical trial costs for VCN-01 and SYN-020. The company recorded $2.8 million in impairment charges for in-process R&D and goodwill.Theriva achieved target enrollment of 92 patients in its Phase 2b VIRAGE trial of VCN-01 for pancreatic cancer. The FDA granted Rare Pediatric Disease Designation to VCN-01 for retinoblastoma treatment. A Phase 1 trial of VCN-01 in brain tumors began enrolling patients. The company's cash position of $16.4 million is expected to fund operations into Q3 2025.Management is exploring strategic options and additional financing to advance clinical programs, particularly later-stage trials of VCN-01. The company faces uncertainty in obtaining sufficient funding to execute its business plan long-term, with its auditors expressing substantial doubt about its ability to continue as a going concern without additional capital.
Theriva生物製品公司公佈了2024年第三季度的財務結果和臨牀進展。營業收入未披露，而淨虧損同比擴大至770萬美元，去年爲330萬美元。研發費用因VCN-01和SYN-020的臨牀試驗成本降低而減少32%，降至270萬美元。該公司記錄了280萬美元的研發在進行中的減值損失和商譽。Theriva在其針對胰腺癌的20億階段VIRAGE試驗中實現了92名患者的目標入組。FDA已授予VCN-01針對視網膜母細胞瘤治療的罕見兒童疾病認定。VCN-01在腦腫瘤的1期試驗已開始招募患者。該公司的現金狀況爲1640萬美元，預計可資助業務運營到2025年第三季度。管理層正在探索戰略選項和額外融資，以推進臨牀項目，尤其是VCN-01的後期試驗。該公司面臨獲得足夠資金以長期執行業務計劃的不確定性，核數師對其在沒有額外資本的情況下繼續作爲持續經營實體的能力表示了重大懷疑。
Theriva生物製品公司公佈了2024年第三季度的財務結果和臨牀進展。營業收入未披露，而淨虧損同比擴大至770萬美元，去年爲330萬美元。研發費用因VCN-01和SYN-020的臨牀試驗成本降低而減少32%，降至270萬美元。該公司記錄了280萬美元的研發在進行中的減值損失和商譽。Theriva在其針對胰腺癌的20億階段VIRAGE試驗中實現了92名患者的目標入組。FDA已授予VCN-01針對視網膜母細胞瘤治療的罕見兒童疾病認定。VCN-01在腦腫瘤的1期試驗已開始招募患者。該公司的現金狀況爲1640萬美元，預計可資助業務運營到2025年第三季度。管理層正在探索戰略選項和額外融資，以推進臨牀項目，尤其是VCN-01的後期試驗。該公司面臨獲得足夠資金以長期執行業務計劃的不確定性，核數師對其在沒有額外資本的情況下繼續作爲持續經營實體的能力表示了重大懷疑。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    相關股票 相關股票
    代碼 迷你走勢 最新價
    知臨集團
    APM
    -- 2.8000
    Coeptis Therapeutics
    COEP
    -- 5.500
    Onconetix
    ONCO
    -- 0.630
    NRX Pharmaceuticals
    NRXP
    -- 2.2000
    Cara Therapeutics
    CARA
    -- 6.120

    解鎖榜首股票